3-D doppler ultrasound helps identify breast cancer

Oct 21, 2008

Three-dimensional (3-D) power Doppler ultrasound helps radiologists distinguish between malignant and benign breast masses, according to a new study being published in the November issue of Radiology.

"Using 3-D scans promises greater accuracy due to more consistent sampling over the entire tumor," said lead author, Gerald L. LeCarpentier, Ph.D., assistant professor in the Department of Radiology at University of Michigan in Ann Arbor. "Our study shows that 3-D power Doppler ultrasound may be useful in the evaluation of some breast masses."

Malignant breast masses often exhibit increased blood flow compared to normal tissue or benign masses. Using 3-D power Doppler ultrasound, radiologists are able to detect vessels with higher flow speeds, which likely indicate cancer.

For the study, Dr. LeCarpentier and colleagues studied 78 women between the ages of 26 and 70 who where scheduled for biopsy of a suspicious breast mass. Each of the women underwent a 3-D Doppler ultrasound exam followed by core or excisional biopsy of the breast.

The results showed that 3-D power Doppler ultrasound was highly accurate in identifying malignant breast tumors. When combined with age-based assessment and gray scale visual analysis, 3-D Doppler showed a sensitivity of 100 percent in identifying cancerous tumors and a specificity of 86 percent in excluding benign tumors.

"Using speed-weighted 3-D power Doppler ultrasound, higher flow velocities in the malignant tumor-feeding vessels may be detected, whereas vessels with slower flow velocities in surrounding benign masses may be excluded," Dr. LeCarpentier said.

Journal link: radiology.rsnajnls.org/

Source: Radiological Society of North America

Explore further: Opdivo approval expanded to include lung cancer

add to favorites email to friend print save as pdf

Related Stories

Google hits back at rivals with futuristic HQ plan

3 hours ago

Google unveiled plans Friday for a new campus headquarters integrating wildlife and sweeping waterways, aiming to make a big statement in Silicon Valley—which is already seeing ambitious projects from Apple ...

Recommended for you

Opdivo approval expanded to include lung cancer

10 hours ago

(HealthDay)—U.S. Food and Drug Administration approval of Opdivo (nivolumab) has been expanded to include advanced non-small cell lung cancer (NSCLC), the agency said Wednesday in a news release.

First-of-its kind reference on pelvic malignancies

11 hours ago

Loyola University Medical Center radiation oncologist William Small, Jr., MD, FACRO, FACR, FASTRO, is co-editor of Pelvic Malignancy and its Consequences, the first-of-its kind stand-alone reference on the subject.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.